Is there funding available for Dexcom Continuous Glucose Monitoring (CGM)?

Although continuous glucose monitors such as the Dexcom G6 are not offered routinely in the UK to all people with type 1 diabetes there is local guidance criteria across the UK for accessing CGM. NICE (The National Institute for Health and Care Excellence) have published guidelines as to when CGM could be considered to help someone with type 1 diabetes. The decision on whether to offer funding to those who meet the guidelines is made at a local CCG (clinical commissioning group) level. Please speak to your local CCG to access details of local policies and guidelines currently in place for CGM.
Dexcom G6 is proven to be cost effective5 and falls well below the cost-effectiveness threshold set by NICE in order to be recommended for NHS funding. Based on the NHS funding criteria, it is estimated that up to 70% of patients with type 1 diabetes may be eligible for the Dexcom G6.6
NICE suggest “The intended place for CGM in therapy is as an alternative to routine blood glucose monitoring in people (over 2 years), including pregnant women, with type 1 diabetes or type 2 diabetes, who use multiple daily insulin injections or insulin pumps and self-manage their diabetes.”
Please refer to NICE Guidance and the Diabetes UK Type 1 Diabetes Technology Consensus Guideline for further details on identifying patients who could benefit from Continuous Glucose Monitoring (CGM) technology, such as Dexcom G6.
Dexcom has developed a patient identification tool to help remind you of the guidance to identify suitable users for Dexcom G6. If you would like to find out more about gaining access to Dexcom G6 speak to your local Dexcom Representative.
Professional Guidelines:

LBL022115 Rev002

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Share are trademark or registered trademarks in the U.S. and may be in other countries.

LBL022115 Rev002

© 2024 Dexcom, Inc. All rights reserved

IE flag

IE

Change region